Imatinib (STI571) in Gastric Cancer Assembloid Research
2026-09-24
Imatinib (STI571) inhibits Abl, PDGF receptor, and c-Kit kinase activity, making it a useful tool for testing kinase-dependent signaling. Patient-derived gastric cancer assembloids provide a way to ask whether matched stromal cells modify responses to this inhibitor, but the assembloid study did not test Imatinib.
BoNT/A Suppresses Ocular Angiogenesis Through SOCS3
2026-09-24
A laser-induced choroidal neovascularization study found that intravitreal botulinum neurotoxin serotype A (BoNT/A) reduced lesion size and vascular leakage while suppressing retinal glial activation. The results implicate neuronal/glial SOCS3 in this protective response and offer a mechanistic direction for studying pathological retinal angiogenesis beyond VEGF alone.
Gap26: Translating Connexin 43 Signaling
2026-09-23
A thought-leadership guide to using Gap26 as a mechanistic probe of connexin 43 communication, with strategic lessons from spinal astrocyte research in breakthrough cancer pain.
SIRT1/2 Inhibitor IV (cambinol) Workflows
2026-09-22
This scenario-based guide explains how SIRT1/2 Inhibitor IV (cambinol), SKU B6063, can support controlled studies of viability, p53 acetylation, apoptosis, lactylation, and tumor biology. It separates product-supported evidence from practical optimization recommendations to help laboratories improve assay interpretation and reproducibility.
Camptothecin at the Adaptive DNA Damage Frontier
2026-09-22
Camptothecin is more than a topoisomerase I inhibitor: it is a controllable probe for DNA damage signaling, cellular fate, autophagy, and adaptive genome behavior. This thought-leadership framework connects established cancer biology workflows with emerging evidence that heritable protein states can reshape mutagenesis under selective pressure.
MMP7–β-Catenin Signaling in Biliary Atresia Fibrosis
2026-09-21
A 2026 study identifies MMP7 as a mechanistic driver of epithelial–mesenchymal transition and liver fibrosis in biliary atresia, linking E-cadherin cleavage to β-catenin nuclear translocation. Its combination of patient samples, transcriptomic analysis, cell experiments, and a chronic mouse model supports MMP7 and the E-cadherin/β-catenin axis as testable antifibrotic targets.
Forskolin Workflows for Pancreatic Organoids
2026-09-21
Use Forskolin as a controlled adenylate cyclase activator to test how cAMP modulation affects pancreatic ductal organoid initiation, composition, and stability. This practical guide connects organoid optimization with stem-cell, neuroendocrine, inflammatory, and cardiovascular disease research while separating reference-backed findings from assay starting points.
Cy5 Goat Anti-Rabbit IgG (H+L) Antibody Workflow
2026-09-20
Translate rabbit-primary immunoassays into sensitive far-red readouts for MAVS, ASB3, and antiviral signaling studies. This workflow combines practical fluorescence optimization with controls that prevent signal amplification from being mistaken for mechanistic proof.
Bufalin Targets STK33 in Triple-Negative Breast Cancer
2026-09-19
A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding partner and degradation target of Bufalin in triple-negative breast cancer. By combining target-discovery assays, mechanistic studies, animal models, and patient-derived organoids, the work connects STK33 loss to reduced tumor growth and provides a framework for evaluating Bufalin as a chemical probe in TNBC research.
Dicloxacillin Activity Against Intracellular S. aureus
2026-09-19
The reference study integrated THP-1 macrophage experiments with a murine peritonitis model to compare dicloxacillin activity against extracellular and intracellular Staphylococcus aureus. Its key translational finding was that free-drug time above the MIC, rather than peak concentration or total exposure alone, best predicted efficacy in both compartments.
RISOTTO Trial: Risedronate for RA-Associated GIO
2026-09-18
The RISOTTO study was a six-month multicentre, double-blind, randomized, placebo-controlled trial evaluating sodium risedronate in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis. Its principal finding was a significantly greater improvement in lumbar spine bone mineral density with risedronate, with no serious adverse events reported, supporting its role in clinically relevant bone metabolism research.
Fritillaria Alkaloids Target MyD88/TRIF Inflammation
2026-09-17
This study identifies four Fritillaria isosteroidal alkaloids that suppress LPS-induced inflammatory responses in macrophages and links their activity to coordinated MyD88-, TRIF-, NF-κB-, and MAPK-related signaling. Ebeiedinone and peimisine also reduced pathological changes in a rat acute lung injury model, supporting further investigation while leaving direct molecular targets and translational efficacy unresolved.
Risedronate Sodium: FPPS Workflows for Bone Research
2026-09-17
Build reproducible Risedronate Sodium experiments around FPPS inhibition, osteoclast-mediated bone resorption inhibition, and lung-targeted delivery. This guide connects solution handling, cell assays, dendrimer formulation, in vivo endpoints, and troubleshooting to evidence from a pulmonary osteoporosis study.
(-)-Arctigenin Workflow for NF-κB and MEK1 Studies
2026-09-16
Build a controlled workflow around (-)-Arctigenin to interrogate LPS-driven iNOS signaling, MEK1 activity, and macrophage–breast cancer communication. The approach combines pathway-resolved dosing with extracellular-vesicle controls, helping distinguish direct pharmacology from changes in tumor-microenvironment signaling.
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-09-16
The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat-derived IgG primary antibodies in ICC/IF, frozen and paraffin tissue staining, flow cytometry, and ELISA. It should not be treated as a universal secondary reagent: it is intended for goat IgG detection and requires assay-specific validation, controls, and fluorescence-compatible instrumentation.